Tapentadol is partly metabolized from the hepatic enzymes CYP2C9, CYP2C19, and CYP2D6 so it innately has interactions with prescription drugs that increase or repress the activity/expression of one or more of those enzymes, and also with substrates of these enzymes (as a consequence of Levels of competition to the enzyme); some enzyme mediators/sub